Dapadrift M 5/1000mg Tablet

DAPADRIFT M 5/1000 mg Tablet is a fixed-dose combination of two oral antidiabetic agents:

• Dapagliflozin (5 mg) – a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor

• Metformin (1000 mg) – a Biguanide class antihyperglycemic agent

This combination helps control blood sugar levels in adults with Type 2 Diabetes Mellitus (T2DM) through complementary mechanisms. Dapagliflozin promotes glucose excretion through the urine, while Metformin reduces glucose production in the liver and improves insulin sensitivity.

USES

• Treatment of Type 2 Diabetes Mellitus (T2DM) in adults

• Used when diet, exercise, and either monotherapy or dual therapy do not provide adequate glycemic control

• May also be used to reduce the risk of cardiovascular events or progression of kidney disease in eligible patients (based on dapagliflozin’s benefits in some patient populations)

BENEFITS

• Dual mechanism for better glycemic control:

  • Dapagliflozin: Increases urinary glucose excretion, lowering blood sugar

  • Metformin: Decreases hepatic glucose output and increases insulin sensitivity

• Weight loss or weight neutral effect (mainly due to dapagliflozin)

• Low risk of hypoglycemia when used without insulin or sulfonylureas

• Cardiovascular and renal protection potential (dapagliflozin has shown benefits in certain patients)

• Improves adherence with convenient fixed-dose combination

SIDE EFFECTS

Common Side Effects:

• Genital fungal infections (more common in females)

• Increased urination

• Urinary tract infections

• Diarrhea, nausea, abdominal discomfort (mainly due to Metformin)

• Headache

Less Common / Serious Side Effects:

• Lactic acidosis (a rare but serious risk with Metformin, especially in renal impairment)

• Dehydration or low blood pressure

• Diabetic ketoacidosis (rare, but serious – associated with SGLT2 inhibitors)

• Hypoglycemia (more likely when used with insulin or sulfonylureas)

• Allergic reactions (rash, itching, swelling – rare)